Viking Therapeutics (VKTX) Institutional Ownership
13F filers reported holding 7.4% of Viking Therapeutics (VKTX) shares as of Sep 30, 2026, across 198 filers.
- Held by 13F filers
- 7.4%
- Sep 30, 2026
- 13F filers
- 198
- quarter ended Sep 30, 2026
- 13F value
- $305.6M
- 9.4M shares
- Quarter's fund flow
- Mild accumulation
- 29 new · 24 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Aug 1, 2026 | Kelly-Gemmell Dorothy Elizabeth | director | Acquired · Grant / award | 6,333 | — | ↗ |
| Aug 1, 2026 | Kelly-Gemmell Dorothy Elizabeth | director | Acquired · Grant / award | 40,800Stock Option (Right to Buy) | — | ↗ |
| Jul 29, 2026 | Lian Brian | President & CEO | Disposed · Open-market sale | 148,517 | $33.32 | ↗ |
| Jul 29, 2026 | ZANTE GREG | Chief Financial Officer | Disposed · Open-market sale | 21,217 | $33.47 | ↗ |
| Jul 29, 2026 | Mancini Marianna | Chief Operating Officer | Disposed · Open-market sale | 18,217 | $33.47 | ↗ |
| Jul 28, 2026 | Lian Brian | President & CEO | Acquired · Grant / award | 221,667 | — | ↗ |
| Jul 28, 2026 | ZANTE GREG | Chief Financial Officer | Acquired · Grant / award | 31,667 | — | ↗ |
| Jul 28, 2026 | Mancini Marianna | Chief Operating Officer | Acquired · Grant / award | 31,667 | — | ↗ |
| Jun 1, 2026 | Chen Hubert C | Chief Medical Officer | Acquired · Grant / award | 190,000Stock Option (Right to Buy) | — | ↗ |
| Mar 10, 2026 | Aubuchon Neil William | Chief Commercial Officer | Acquired · Open-market buy | 4,475 | $33.50 | ↗ |
| Jan 12, 2026 | Aubuchon Neil William | Chief Commercial Officer | Acquired · Grant / award | 180,000Stock Option (Right to Buy) | — | ↗ |
| Jan 5, 2026 | ZANTE GREG | Chief Financial Officer | Disposed · Open-market sale | 31,961 | $32.30 | ↗ |
| Jan 5, 2026 | ZANTE GREG | Chief Financial Officer | Disposed · Open-market sale | 13,900 | $33.38 | ↗ |
| Jan 5, 2026 | ZANTE GREG | Chief Financial Officer | Disposed · Open-market sale | 10,300 | $34.24 | ↗ |
| Jan 5, 2026 | ZANTE GREG | Chief Financial Officer | Disposed · Open-market sale | 1,500 | $32.09 | ↗ |
| Jan 5, 2026 | Mancini Marianna | Chief Operating Officer | Disposed · Open-market sale | 31,961 | $32.29 | ↗ |
| Jan 5, 2026 | Mancini Marianna | Chief Operating Officer | Disposed · Open-market sale | 13,600 | $33.37 | ↗ |
| Jan 5, 2026 | Mancini Marianna | Chief Operating Officer | Disposed · Open-market sale | 10,500 | $34.22 | ↗ |
| Jan 5, 2026 | Mancini Marianna | Chief Operating Officer | Disposed · Open-market sale | 1,600 | $35.07 | ↗ |
| Jan 5, 2026 | Lian Brian | President & CEO | Disposed · Open-market sale | 132,454 | $32.29 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Viking Therapeutics do institutions hold?
13F filers reported holding 7.4% of Viking Therapeutics' shares as of Sep 30, 2026, across 198 filers.
How many 13F filers hold Viking Therapeutics?
Viking Therapeutics was held by 198 13F filers as of Sep 30, 2026.
Not investment advice.

